Shockwave Medical, Inc. (NASDAQ:SWAV) Given Consensus Rating of “Hold” by Analysts

Shares of Shockwave Medical, Inc. (NASDAQ:SWAV) have received a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Ten research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $309.11.

SWAV has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $335.00 price objective (up from $270.00) on shares of Shockwave Medical in a research note on Monday, April 8th. Wolfe Research reissued a “peer perform” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Needham & Company LLC reissued a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Wells Fargo & Company increased their target price on shares of Shockwave Medical from $200.00 to $210.00 and gave the stock an “equal weight” rating in a research report on Friday, February 16th. Finally, Leerink Partnrs downgraded shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, April 5th.

Shockwave Medical Stock Down 0.1 %

Shares of Shockwave Medical stock opened at $329.84 on Friday. Shockwave Medical has a 52-week low of $157.00 and a 52-week high of $331.58. The company has a 50 day moving average of $299.06 and a 200 day moving average of $236.28. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $12.37 billion, a P/E ratio of 85.23, a P/E/G ratio of 2.45 and a beta of 0.92.

Shockwave Medical (NASDAQ:SWAV) last released its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.24. The company had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a net margin of 20.17% and a return on equity of 23.97%. The firm’s revenue for the quarter was up 41.0% on a year-over-year basis. During the same quarter last year, the company earned $3.71 earnings per share. As a group, research analysts forecast that Shockwave Medical will post 4.94 EPS for the current fiscal year.

Insider Transactions at Shockwave Medical

In other Shockwave Medical news, VP Trinh Phung sold 1,287 shares of Shockwave Medical stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the completion of the transaction, the vice president now owns 32,933 shares of the company’s stock, valued at $7,646,383.94. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Shockwave Medical news, Director Frederic H. Moll sold 60,000 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $257.39, for a total value of $15,443,400.00. Following the sale, the director now directly owns 287,521 shares in the company, valued at $74,005,030.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Trinh Phung sold 1,287 shares of the firm’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the completion of the sale, the vice president now owns 32,933 shares in the company, valued at $7,646,383.94. The disclosure for this sale can be found here. Over the last quarter, insiders sold 86,407 shares of company stock valued at $22,081,356. 3.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Shockwave Medical

Hedge funds have recently added to or reduced their stakes in the stock. YHB Investment Advisors Inc. bought a new stake in shares of Shockwave Medical during the first quarter valued at about $28,000. Riverview Trust Co bought a new stake in Shockwave Medical in the first quarter worth about $30,000. Rise Advisors LLC purchased a new position in Shockwave Medical in the 1st quarter worth about $32,000. GAMMA Investing LLC increased its stake in Shockwave Medical by 92.9% in the 1st quarter. GAMMA Investing LLC now owns 135 shares of the company’s stock worth $44,000 after purchasing an additional 65 shares in the last quarter. Finally, Lindbrook Capital LLC increased its stake in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares in the last quarter. 95.35% of the stock is currently owned by institutional investors.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.